Opportunity Information: Apply for EDS EDS 26 001
The Office of National Drug Control Policy is offering a discretionary cooperative agreement for a research project focused on nonfatal overdoses seen in emergency departments, with an emphasis on connecting three critical pieces of information that are often studied separately: patient characteristics, biospecimen toxicology results, and the changing composition of the local drug supply. The central idea is to improve how communities and the nation understand what substances are actually being used and causing harm, by linking what clinicians observe in the emergency setting with what laboratory testing confirms and what public safety or public health intelligence indicates is circulating in the drug market.
The opportunity is titled "Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition" (Funding Opportunity Number: EDS EDS 26 001). It is categorized under health and uses a cooperative agreement structure, which typically means the federal agency expects to have substantial involvement during the project period, such as collaborating on project direction, coordination, data-sharing approaches, or dissemination strategies. The program is tied to CFDA number 95.007.
The project is intended to strengthen both local and national drug consumption surveillance. In practical terms, that means improving the ability to detect and track what drugs or drug combinations are driving overdose events, how those patterns vary across populations, and how quickly new substances or adulterants appear and spread. By centering emergency departments, the work leverages a key point of contact where overdoses are treated and documented in near real time, creating an opportunity to make surveillance more timely, consistent, and actionable.
A major objective is to identify gaps in existing drug testing protocols. Many overdose cases are evaluated with limited toxicology testing, and standard panels may miss emerging synthetic opioids, novel benzodiazepines, xylazine, stimulants, or other substances that can shape clinical outcomes and public health response. This grant is positioned to surface where testing falls short, how biospecimen toxicology can be improved or modernized, and how testing results can be better integrated with clinical and demographic information to support both patient care insights and broader situational awareness.
Another key purpose is facilitating information exchange across public health and public safety organizations. The drug supply evolves quickly, and information is often siloed between hospitals, laboratories, medical examiners, poison centers, public health departments, law enforcement, and community response groups. This project aims to help bridge those silos so that findings from emergency department overdose presentations and biospecimen toxicology can be shared in ways that support coordinated decision-making, targeted alerts, and interventions that match what is actually happening on the ground.
The award has a ceiling of $500,000, with one expected award. Eligible applicants include public and state-controlled institutions of higher education and nonprofit organizations with 501(c)(3) status (excluding institutions of higher education where applicable). The opportunity was created on 2026-08-12, and the original closing date is 2026-08-31, indicating a relatively tight application window.
Overall, this grant supports a focused, high-impact research effort to improve the accuracy and usefulness of overdose surveillance by tying together who is overdosing, what substances are confirmed in biospecimens, and what is known about the local drug supply. The intended outcome is a more informed, better coordinated response to the drug crisis, driven by stronger data, clearer testing insights, and faster cross-sector communication.Apply for EDS EDS 26 001
- The Office of National Drug Control Policy in the health sector is offering a public funding opportunity titled "Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 95.007.
- This funding opportunity was created on 2026-08-12.
- Applicants must submit their applications by 2026-08-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The opportunity is titled "Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is EDS EDS 26 001.
Which federal office is offering this award?
The award is offered by the Office of National Drug Control Policy (ONDCP).
What type of funding mechanism is being used?
This is a discretionary cooperative agreement.
What does a cooperative agreement imply for how the project will be run?
A cooperative agreement structure typically means the federal agency expects substantial involvement during the project period. Based on the opportunity description, that involvement may include collaboration on project direction, coordination, data-sharing approaches, and/or dissemination strategies.
What is the CFDA number associated with this program?
The program is tied to CFDA number 95.007.
What is the main focus of the research project?
The project focuses on nonfatal overdoses seen in emergency departments, with an emphasis on connecting three pieces of information that are often studied separately: patient characteristics, biospecimen toxicology results, and the changing composition of the local drug supply.
What problem is this opportunity trying to solve?
The central goal is to improve understanding of what substances are actually being used and causing harm by linking (1) what clinicians observe in emergency settings, (2) what laboratory testing confirms through biospecimen toxicology, and (3) what public safety or public health intelligence indicates is circulating in the drug market.
Why are emergency departments central to this effort?
Emergency departments are a key point of contact where overdoses are treated and documented in near real time. Centering emergency departments is intended to make drug consumption surveillance more timely, consistent, and actionable.
What does "drug consumption surveillance" mean in the context of this grant?
In this context, it refers to improving the ability to detect and track what drugs or drug combinations are driving overdose events, how patterns vary across populations, and how quickly new substances or adulterants appear and spread.
What types of data does the project aim to bridge?
The project aims to bridge: (1) patient characteristics (including clinical and demographic information as described), (2) biospecimen toxicology results, and (3) information about local drug supply composition.
What are biospecimen toxicology results, as used here?
In this opportunity, biospecimen toxicology refers to laboratory testing results from biospecimens collected in connection with emergency department overdose cases, used to confirm what substances are present.
What are examples of substances that standard toxicology panels may miss?
The description notes that standard panels may miss emerging synthetic opioids, novel benzodiazepines, xylazine, stimulants, or other substances that can influence clinical outcomes and public health response.
What is meant by identifying gaps in drug testing protocols?
A major objective is to surface where existing overdose-related drug testing falls short (for example, when toxicology testing is limited or standard panels fail to detect emerging substances), and to explore how biospecimen toxicology can be improved or modernized.
How is the project expected to use the linked data once it is connected?
The opportunity emphasizes integrating toxicology results with clinical and demographic information to support patient care insights and broader situational awareness, as well as aligning findings with what is known about the local drug supply.
What is meant by "local drug supply composition" in this opportunity?
It refers to what substances, mixtures, or adulterants are circulating in the local drug market, as indicated by public safety or public health intelligence.
Why does the opportunity emphasize information exchange across organizations?
The drug supply evolves quickly and information is often siloed among hospitals, laboratories, medical examiners, poison centers, public health departments, law enforcement, and community response groups. This project aims to bridge those silos so findings can support coordinated decision-making, targeted alerts, and interventions aligned with real-world conditions.
What kinds of organizations are specifically mentioned as being part of the current "siloed" landscape?
The opportunity specifically mentions hospitals, laboratories, medical examiners, poison centers, public health departments, law enforcement, and community response groups.
What outcomes is ONDCP aiming for through this award?
The intended outcome is a more informed, better coordinated response to the drug crisis, driven by stronger data, clearer testing insights, and faster cross-sector communication.
How many awards are expected to be made?
One award is expected.
What is the maximum award amount (ceiling)?
The award ceiling is $500,000.
Who is eligible to apply?
Eligible applicants include public and state-controlled institutions of higher education and nonprofit organizations with 501(c)(3) status (excluding institutions of higher education where applicable).
What is the category or field for this opportunity?
The opportunity is categorized under health.
When was this opportunity created?
It was created on 2026-08-12.
What is the closing date for applications?
The original closing date is 2026-08-31.
How much time is there between the created date and the closing date?
Based on the provided dates (created 2026-08-12 and closing 2026-08-31), the application window is relatively tight.
Is this opportunity focused on fatal overdoses or nonfatal overdoses?
This opportunity is focused on nonfatal overdoses seen in emergency departments.
What makes this project approach different from typical overdose studies?
The opportunity highlights that patient characteristics, biospecimen toxicology results, and drug supply composition are often studied separately. This project is designed to connect those elements to improve the accuracy and usefulness of overdose surveillance.
What is the practical benefit of linking emergency department observations with toxicology and drug supply intelligence?
Linking these sources is intended to improve understanding of what substances are actually being used and causing harm, enhance detection and tracking of changing drug patterns, and support coordinated alerts and interventions based on confirmed and current information.
Browse more opportunities from the same category: Health
Next opportunity: Annual Recurring University Training and Research
Previous opportunity: Global Digital Threat Lab
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for EDS EDS 26 001
Applicants also applied for:
Applicants who have applied for this opportunity (EDS EDS 26 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improving The Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 001 Funding Number: RD ET RDA 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "EDS EDS 26 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.